Table of Content
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Overview
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Companies Involved in Therapeutics Development
AMar AB
Daya Drug Discoveries Inc
Neurim Pharmaceuticals Ltd
RaQualia Pharma Inc
Reviva Pharmaceuticals Inc
Seropeutics LLC
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Drug Profiles
AM-1476 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Antagonize HTR2B for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize HTR2B for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize HTR2B for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Dormant Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Discontinued Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Product Development Milestones
Featured News & Press Releases
Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia
Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmory fibrosis
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Desigtion for RP5063 for the Treatment of Idiopathic Pulmory Fibrosis (IPF)
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmory Arterial Hypertension
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer’s Disease
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Desigtion for Pulmory Arterial Hypertension (PAH)
Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION
List of Figures
List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
List of Tables
List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AnaMar AB, 2021
Pipeline by Daya Drug Discoveries Inc, 2021
Pipeline by Neurim Pharmaceuticals Ltd, 2021
Pipeline by RaQualia Pharma Inc, 2021
Pipeline by Reviva Pharmaceuticals Inc, 2021
Pipeline by Seropeutics LLC, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021